Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?
Anaplastic thyroid carcinoma (ATC) is a rare and aggressive form of thyroid carcinoma (TC). Currently, there are no effective treatments for this condition. In the past few years, targeted therapy and immunotherapy have made significant progress in ATC treatment. Several common genetic mutations hav...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1103147/full |
| _version_ | 1797868248000102400 |
|---|---|
| author | Xiaoni Gao Xiaoni Gao Chengcheng Hong Yang Xie Yang Xie Xiangtai Zeng Xiangtai Zeng |
| author_facet | Xiaoni Gao Xiaoni Gao Chengcheng Hong Yang Xie Yang Xie Xiangtai Zeng Xiangtai Zeng |
| author_sort | Xiaoni Gao |
| collection | DOAJ |
| description | Anaplastic thyroid carcinoma (ATC) is a rare and aggressive form of thyroid carcinoma (TC). Currently, there are no effective treatments for this condition. In the past few years, targeted therapy and immunotherapy have made significant progress in ATC treatment. Several common genetic mutations have been found in ATC cells, involving different molecular pathways related to tumor progression, and new therapies that act on these molecular pathways have been studied to improve the quality of life of these patients. In 2018, the FDA approved dabrafenib combined with trametinib to treat BRAF-positive ATC, confirming its therapeutic potential. At the same time, the recent emergence of immunotherapy has also attracted wide attention from researchers. While immunotherapy for ATC is still in the experimental stage, numerous studies have shown that immunotherapy is a potential therapy for ATC. In addition, it has also been found that the combination of immunotherapy and targeted therapy may enhance the anti-tumor effect of targeted therapy. In recent years, there has been some progress in the study of targeted therapy or immunotherapy combined with radiotherapy or chemotherapy, showing the prospect of combined therapy in ATC. In this review, we analyze the response mechanism and potential effects of targeted therapy, immunotherapy, and combination therapy in ATC treatment and explore the future of treatment for ATC. |
| first_indexed | 2024-04-09T23:52:59Z |
| format | Article |
| id | doaj.art-da3f7df54b46437b93de39969ad8e3f6 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-09T23:52:59Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-da3f7df54b46437b93de39969ad8e3f62023-03-17T05:20:22ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-03-011310.3389/fonc.2023.11031471103147Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?Xiaoni Gao0Xiaoni Gao1Chengcheng Hong2Yang Xie3Yang Xie4Xiangtai Zeng5Xiangtai Zeng6Department of Thyroid and Hernia Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, ChinaGanzhou Key Laboratory of Thyroid Cancer, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, ChinaGanzhou Key Laboratory of Thyroid Cancer, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, ChinaDepartment of Thyroid and Hernia Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, ChinaGanzhou Key Laboratory of Thyroid Cancer, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, ChinaDepartment of Thyroid and Hernia Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, ChinaInstitute of Thyroid Diseases, Gannan Medical University, Ganzhou, Jiangxi, ChinaAnaplastic thyroid carcinoma (ATC) is a rare and aggressive form of thyroid carcinoma (TC). Currently, there are no effective treatments for this condition. In the past few years, targeted therapy and immunotherapy have made significant progress in ATC treatment. Several common genetic mutations have been found in ATC cells, involving different molecular pathways related to tumor progression, and new therapies that act on these molecular pathways have been studied to improve the quality of life of these patients. In 2018, the FDA approved dabrafenib combined with trametinib to treat BRAF-positive ATC, confirming its therapeutic potential. At the same time, the recent emergence of immunotherapy has also attracted wide attention from researchers. While immunotherapy for ATC is still in the experimental stage, numerous studies have shown that immunotherapy is a potential therapy for ATC. In addition, it has also been found that the combination of immunotherapy and targeted therapy may enhance the anti-tumor effect of targeted therapy. In recent years, there has been some progress in the study of targeted therapy or immunotherapy combined with radiotherapy or chemotherapy, showing the prospect of combined therapy in ATC. In this review, we analyze the response mechanism and potential effects of targeted therapy, immunotherapy, and combination therapy in ATC treatment and explore the future of treatment for ATC.https://www.frontiersin.org/articles/10.3389/fonc.2023.1103147/fullimmunotherapytargeted therapyanaplastic thyroid cancer (ATC)immune checkpoint blockadeMAPKPI3K |
| spellingShingle | Xiaoni Gao Xiaoni Gao Chengcheng Hong Yang Xie Yang Xie Xiangtai Zeng Xiangtai Zeng Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma? Frontiers in Oncology immunotherapy targeted therapy anaplastic thyroid cancer (ATC) immune checkpoint blockade MAPK PI3K |
| title | Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma? |
| title_full | Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma? |
| title_fullStr | Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma? |
| title_full_unstemmed | Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma? |
| title_short | Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma? |
| title_sort | immunotherapy or targeted therapy what will be the future treatment for anaplastic thyroid carcinoma |
| topic | immunotherapy targeted therapy anaplastic thyroid cancer (ATC) immune checkpoint blockade MAPK PI3K |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1103147/full |
| work_keys_str_mv | AT xiaonigao immunotherapyortargetedtherapywhatwillbethefuturetreatmentforanaplasticthyroidcarcinoma AT xiaonigao immunotherapyortargetedtherapywhatwillbethefuturetreatmentforanaplasticthyroidcarcinoma AT chengchenghong immunotherapyortargetedtherapywhatwillbethefuturetreatmentforanaplasticthyroidcarcinoma AT yangxie immunotherapyortargetedtherapywhatwillbethefuturetreatmentforanaplasticthyroidcarcinoma AT yangxie immunotherapyortargetedtherapywhatwillbethefuturetreatmentforanaplasticthyroidcarcinoma AT xiangtaizeng immunotherapyortargetedtherapywhatwillbethefuturetreatmentforanaplasticthyroidcarcinoma AT xiangtaizeng immunotherapyortargetedtherapywhatwillbethefuturetreatmentforanaplasticthyroidcarcinoma |